MedTrace Logo

Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)

NCT07166211 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-04-09

No results posted yet for this study

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with CSU.

Conditions

  • Chronic Spontaneous Urticaria (CSU)

Interventions

BIOLOGICAL

CM512 injection

subcutaneous injection

DRUG

placebo

subcutaneous injection

Sponsors & Collaborators

  • Keymed Biosciences Co.Ltd

    lead INDUSTRY

Principal Investigators

  • Litao Zhang · Tianjin Academy of Traditional Chinese Medicine Affiliate Hospital

  • Zuotao Zhao · Tianjin Academy of Traditional Chinese Medicine Affiliate Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-27
Primary Completion
2026-11-02
Completion
2027-01-14

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07166211 on ClinicalTrials.gov